# A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

> **NCT06812117** · — · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 721 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **OTHER:** No Drug

## Key facts

- **NCT ID:** NCT06812117
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2026-07-24
- **Final completion:** 2026-07-24
- **Target enrollment:** 721 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812117, "A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06812117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*